The role of myeloid-derived suppressor cells in patients with solid tumors: A meta-analysis

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Zhang, Shuo ^a   Ma, Xuelei ^a   Zhu, Chenjing ^a   Liu, Li ^a   Wang, Guoping ^a   Yuan, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; ASIAN; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HODGKIN DISEASE; HUMAN; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; MYELOID DERIVED SUPPRESSOR CELL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; SOLID TUMOR; STOMACH CANCER; SUPPRESSOR CELL; META ANALYSIS; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASM; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

DISEASE-FREE SURVIVAL; HUMANS; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84992723893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0164514     Document Type: Article

References (50)

1. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. (1474-1768 (Electronic)). doi: D-NLM: NIHMS562329.D-NLM: PMC3967236 EDAT-2012/03/23 06:00 MHDA-2012/05/16 06:00 CRDT-2012/03/23 06:00 AID-nrc3237 [pii] AID-doi: 10.1038/nrc3237 PST-epublish. 22437869
2. Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Asia; an overview. (2008-2258 (Print)). doi: D-NLM: PMC4285928 OTO-NOTNLM.
3. Rasch S, Algul H. A clinical perspective on the role of chronic inflammation in gastrointestinal cancer. (1178-7023 (Electronic)). doi: D-NLM: PMC4134025 OTO-NOTNLM.
4. Ferlay J, Soerjomataram I Fau-Dikshit R, Dikshit R Fau-Eser S, Eser S Fau-Mathers C, Mathers C Fau-Rebelo M, Rebelo M Fau-Parkin DM, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. (1097-0215 (Electronic)).
5. Prasad S, Tyagi AK. Ginger and its constituents: role in prevention and treatment of gastrointestinal cancer. (1687-6121 (Print)). doi: D-NLM: PMC4369959 EDAT-2015/04/04 06:00 MHDA-2015/04/04 06:01 CRDT-2015/04/04 06:00 PHST-2014/10/29 [received] PHST-2015/01/20 [revised] PHST-2015/02/16 [accepted] PHST-2015/03/08 [epublish] AID-doi: 10.1155/2015/142979 PST-ppublish. 25838819
6. Rozen P. Cancer of the gastrointestinal tract: early detection or early prevention? (0959-8278 (Print)).
7. Okawa T, Kita-Okawa M. [The role and future of radiotherapy in cancer treatment]. (0385-0684 (Print)).
8. Romond EH, Perez Ea Fau-Bryant J, Bryant J Fau-Suman VJ, Suman Vj Fau-Geyer CE, Jr., Geyer Ce Jr Fau-Davidson NE, Davidson Ne Fau-Tan-Chiu E, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. (1533-4406 (Electronic)).
9. Soliman H. Developing an effective breast cancer vaccine. (1526-2359 (Electronic)).
10. Soliman H. Immunotherapy strategies in the treatment of breast cancer. (1526-2359 (Electronic)).
11. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. (1573-7233 (Electronic)).
12. Sun HL, Zhou X Fau-Xue Y-F, Xue Yf Fau-Wang K, Wang K Fau-Shen Y-F, Shen Yf Fau-Mao JJ, Mao Jj Fau-Guo H-F, et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. (2219-2840 (Electronic)). doi: D-NLM: PMC3391769 OTO-NOTNLM.
13. Gabitass RF, Annels Ne Fau-Stocken DD, Stocken Dd Fau-Pandha HA, Pandha Ha Fau-Middleton GW, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. (1432-0851 (Electronic)). doi: D-NLM: PMC3176406 EDAT-2011/06/07 06:00 MHDA-2011/11/04 06:00 CRDT-2011/06/07 06:00 PHST-2010/12/17 [received] PHST-2011/04/22 [accepted] PHST-2011/06/05 [aheadofprint] AID-doi: 10.1007/s00262-011-1028-0 PST-ppublish. 21644036
14. Lindau D, Gielen P Fau-Kroesen M, Kroesen M Fau-Wesseling P, Wesseling P Fau-Adema GJ, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. (1365-2567 (Electronic)). doi: D-NLM: PMC3575763 EDAT-2012/12/12 06:00 MHDA-2013/03/12 06:00 CRDT-2012/12/11 06:00 PHST-2012/07/03 [received] PHST-2012/10/25 [revised] PHST-2012/10/29 [accepted] AID-doi: 10.1111/imm.12036 PST-ppublish. 23216602
15. Gabrilovich DI, Ostrand-Rosenberg S Fau-Bronte V, Bronte V. Coordinated regulation of myeloid cells by tumours. (1474-1741 (Electronic)). doi: D-NLM: NIHMS442658 D-NLM: PMC3587148 EDAT-2012/03/23 06:00 MHDA-2012/07/10 06:00 CRDT-2012/03/23 06:00 AID-nri3175 [pii] AID-doi: 10.1038/nri3175 PST-epublish. 22437938
16. Murdoch C, MuthanaM Fau-Coffelt SB, Coffelt Sb Fau-Lewis CE, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. (1474-1768 (Electronic)).
17. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. (1432-0851 (Electronic)). doi: D-NLM: NIHMS484892 D-NLM: PMC3706261 EDAT-2010/04/24 06:00 MHDA-2010/08/17 06:00 CRDT-2010/04/24 06:00 PHST-2010/03/10 [received] PHST-2010/04/01 [accepted] PHST-2010/04/23 [aheadofprint] AID-doi: 10.1007/s00262-010-0855-8 PST-ppublish. 20414655
18. Mirghorbani M, Van Gool S Fau-Rezaei N, Rezaei N. Myeloid-derived suppressor cells in glioma. (1744-8360 (Electronic)).
19. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. (1550-6606 (Electronic)). doi: D-NLM: NIHMS166179 D-NLM: PMC2810498 EDAT-2009/04/04 09:00 MHDA-2009/04/25 09:00 CRDT-2009/04/04 09:00 AID-182/8/4499 [pii] AID-doi: 10.4049/jimmunol.0802740 PST-ppublish. 19342621
20. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. (1521-4141 (Electronic)). doi: D-NLM: NIHMS354073 D-NLM: PMC3277452 EDAT-2010/11/10 06:00 MHDA-2010/12/18 06:00 CRDT-2010/11/10 06:00 AID-doi: 10.1002/eji.201040895 PST-ppublish. 21061430
21. Duffy A, Zhao F Fau-Haile L, Haile L Fau-Gamrekelashvili J, Gamrekelashvili J Fau-Fioravanti S, Fioravanti S Fau-Ma C, Ma C Fau-Kapanadze T, et al. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. (1432-0851 (Electronic)).
22. Weinstein EJ, Kitsberg Di Fau-Leder P, Leder P. A mouse model for breast cancer induced by amplification and overexpression of the neu promoter and transgene. (1076-1551 (Print)). doi: D-NLM: PMC1949912 EDAT-2000/05/10 09:00 MHDA-2000/06/17 09:00 CRDT-2000/05/10 09:00 PST-ppublish.
23. Habibi M, Kmieciak M Fau-Graham L, Graham L Fau-Morales JK, Morales Jk Fau-Bear HD, Bear Hd Fau-Manjili MH, Manjili MH. Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. (1573-7217 (Electronic)). doi: D-NLM: NIHMS48581 D-NLM: PMC2649692 EDAT-2008/04/22 09:00 MHDA-2009/08/26 09:00 CRDT-2008/04/22 09:00 PHST-2008/03/05 [received] PHST-2008/04/10 [accepted] PHST-2008/04/20 [aheadofprint] AID-doi: 10. 1007/s10549-008-0024-3 PST-ppublish. 18425677
24. Baek JY, HurWFau-Wang JS, Wang Js Fau-Bae SH, Bae Sh Fau-Yoon SK, Yoon SK. Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest. (1007-9327 (Print)). doi: D-NLM: PMC4146990 EDAT-2007/04/25 09:00 MHDA-2007/07/18 09:00 CRDT-2007/04/25 09:00 PST-ppublish.
25. Albeituni SH, Ding C Fau-Yan J, Yan J. Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. (1540-336X (Electronic)). doi: D-NLM: NIHMS542799 D-NLM: PMC3902636 EDAT-2013/11/26 06:00 MHDA-2014/09/10 06:00 CRDT-2013/11/26 06:00 AID-doi: 10.1097/PPO.0000000000000006 AID-00130404-201311000-00006 [pii] PST-ppublish. 24270348
26. Markowitz J, Wesolowski R Fau-Papenfuss T, Papenfuss T Fau-Brooks TR, Brooks Tr Fau-Carson WE, 3rd, Carson WE, 3rd. Myeloid-derived suppressor cells in breast cancer. (1573-7217 (Electronic)). doi: D-NLM: NIHMS502408 D-NLM: PMC3773691 EDAT-2013/07/06 06:00 MHDA-2014/02/11 06:00 CRDT-2013/07/06 06:00 PHST-2013/06/03 [received] PHST-2013/06/20 [accepted] PHST-2013/07/05 [aheadofprint] AID-doi: 10.1007/s10549-013-2618-7 PST-ppublish. 23828498
27. Quante M, Varga J Fau-Wang TC, Wang Tc Fau-Greten FR, Greten FR. The gastrointestinal tumor microenvironment. (1528-0012 (Electronic)). doi: D-NLM: NIHMS466894 D-NLM: PMC4012393 EDAT-2013/04/16 06:00 MHDA-2013/12/16 06:00 CRDT-2013/04/16 06:00 PHST-2013/01/29 [received] PHST-2013/03/27 [revised] PHST-2013/03/28 [accepted] PHST-2013/04/10 [aheadofprint] AID-S0016-5085(13)00501-5 [pii] AID-doi: 10.1053/j.gastro.2013.03.052 PST-ppublish. 23583733
28. Moher D, Shamseer L Fau-Clarke M, Clarke M Fau-Ghersi D, Ghersi D Fau-Liberati A, Liberati A Fau-Petticrew M, PetticrewM Fau-Shekelle P, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. (2046-4053 (Electronic)). doi: D-NLM: PMC4320440.
29. Parmar MK, Torri V Fau-Stewart L, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. (0277-6715 (Print)).
30. Tierney JF, Stewart La Fau-Ghersi D, Ghersi D Fau-Burdett S, Burdett S Fau-Sydes MR, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. (1745-6215 (Electronic)). doi: D-NLM: PMC1920534 EDAT-2007/06/09 09:00 MHDA-2007/06/09 09:01 CRDT-2007/06/09 09:00 PHST-2006/09/25 [received] PHST-2007/06/07 [accepted] PHST-2007/06/07 [aheadofprint] AID-1745-6215-8-16 [pii] AID-doi: 10.1186/1745-6215-8-16 PST-epublish. 17555582
31. Higgins JP, Thompson Sg Fau-Deeks JJ, Deeks Jj Fau-Altman DG, Altman DG. Measuring inconsistency in meta-analyses. (1756-1833 (Electronic)). doi: D-NLM: PMC192859 EDAT-2003/09/06 05:00 MHDA-2003/09/16 05:00 CRDT-2003/09/06 05:00 AID-doi: 10.1136/bmj.327.7414.557 AID-327/7414/557 [pii] PST-ppublish. 12958120
32. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. (0193-936X (Print)).
33. DerSimonian R Fau-Laird N, Laird N. Meta-analysis in clinical trials. (0197-2456 (Print)).
34. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. (0895-4356 (Print)).
35. Taggart DP, D'Amico R Fau-Altman DG, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. (0140-6736 (Print)).
36. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. (1573-7284 (Electronic)).
37. Wang D, An G, Xie S, Yao Y, Feng G. The clinical and prognostic significance of CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. (1423-0380 (Electronic)).
38. Arihara F, Mizukoshi E Fau-Kitahara M, Kitahara M Fau-Takata Y, Takata Y Fau-Arai K, Arai K Fau-Yamashita T, Yamashita T Fau-Nakamoto Y, et al. Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. (1432-0851 (Electronic)).
39. Solito S, Falisi E Fau-Diaz-Montero CM, Diaz-Montero Cm Fau-Doni A, Doni A Fau-Pinton L, Pinton L Fau-Rosato A, Rosato A Fau-Francescato S, et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. (1528-0020 (Electronic)). doi: D-NLM: PMC3709641 EDAT-2011/07/08 06:00 MHDA-2011/10/25 06:00 CRDT-2011/07/08 06:00 PHST-2011/07/06 [aheadofprint] AID-blood-2010-12-325753 [pii] AID-doi: 10. 1182/blood-2010-12-325753 PST-ppublish. 21734236
40. Romano A, Parrinello Nl Fau-Vetro C, Vetro C Fau-Forte S, Forte S Fau-Chiarenza A, Chiarenza A Fau-Figuera A, Figuera A Fau-Motta G, et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. (1365-2141 (Electronic)).
41. Gabrilovich DI. Editorial: The intricacy of choice: can bacteria decide what type of myeloid cells to stimulate? (1938-3673 (Electronic)). doi: D-NLM: PMC4197560 OTO-NOTNLM.
42. Zhang QW, Liu L Fau-Gong C-y, Gong Cy Fau-Shi H-s, Shi Hs Fau-Zeng Y-h, Zeng Yh Fau-Wang X-z, Wang Xz Fau-Zhao Y-w, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. (1932-6203 (Electronic)). doi: D-NLM: PMC3532403 EDAT-2013/01/04 06:00 MHDA-2013/06/19 06:00 CRDT-2013/01/04 06:00 PHST-2012/06/19 [received] PHST-2012/10/29 [accepted] PHST-2012/12/28 [epublish] AID-doi: 10.1371/journal. pone.0050946 AID-PONE-D-12-17794 [pii] PST-ppublish. 23284651
43. Shen P, Wang A Fau-He M, He M Fau-Wang Q, Wang Q Fau-Zheng S, Zheng S. Increased circulating Lin(-/low) CD33(+) HLA-DR(-) myeloid-derived suppressor cells in hepatocellular carcinoma patients. (1386-6346 (Print)).
44. Mundy-Bosse BL, Young Gs Fau-Bauer T, Bauer T Fau-Binkley E, Binkley E Fau-Bloomston M, BloomstonM Fau-Bill MA, Bill Ma Fau-Bekaii-Saab T, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4(+) T cells from patients with GI malignancy. (1432-0851 (Electronic)). doi: D-NLM: NIHMS425282D-NLM: PMC3521517 EDAT-2011/05/24 06:00 MHDA-2011/12/13 00:00 CRDT-2011/05/24 06:00 PHST-2011/02/28 [received] PHST-2011/04/25 [accepted] PHST-2011/05/21 [aheadofprint] AID-doi: 10. 1007/s00262-011-1029-z PST-ppublish. 21604071
45. Galon J Fau-Pages F, Pages F Fau-Marincola FM, Marincola Fm Fau-Thurin M, Thurin M Fau-Trinchieri G, Trinchieri G Fau-Fox BA, Fox Ba Fau-Gajewski TF, et al. The immune score as a new possible approach for the classification of cancer. (1479-5876 (Electronic)). doi: D-NLM: PMC3269368 EDAT-2012/01/05 06:00 MHDA-2012/05/19 06:00 CRDT-2012/01/05 06:00 PHST-2011/12/20 [received] PHST-2012/01/03 [accepted] PHST-2012/01/03 [aheadofprint] AID-1479-5876-10-1 [pii] AID-doi: 10.1186/1479-5876-10-1 PST-epublish. 22214470
46. Galon J, Mlecnik B Fau-Bindea G, Bindea G Fau-Angell HK, Angell Hk Fau-Berger A, Berger A Fau-Lagorce C, Lagorce C Fau-Lugli A, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. (1096-9896 (Electronic)). doi: D-NLM: PMC4255306 OTO-NOTNLM.
47. Fujimura T, Mahnke K Fau-Enk AH, Enk AH. Myeloid derived suppressor cells and their role in tolerance induction in cancer. (1873-569X (Electronic)).
48. Waldron TJ, Quatromoni Jg Fau-Karakasheva TA, Karakasheva Ta Fau-Singhal S, Singhal S Fau-Rustgi AK, Rustgi AK. Myeloid derived suppressor cells: Targets for therapy. (2162-4011 (Print)).
49. Yang L, DeBusk Lm Fau-Fukuda K, Fukuda K Fau-Fingleton B, Fingleton B Fau-Green-Jarvis B, Green-Jarvis B Fau-Shyr Y, Shyr Y Fau-Matrisian LM, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. (1535-6108 (Print)).
50. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. BMJ (Clinical research ed). 2009; 339:b2535. Epub 2009/07/23. doi: 10.1136/bmj.b2535 PMID: 19622551; PubMed Central PMCID: PMCPMC2714657.